Source: Plant Veda
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Plant Veda (MILK) has received export approval from the Canadian Food Inspection Agency (CFIA)
  • The approval is for the company’s new facility in Delta, British Columbia.
  • The company’s facility has also been registered with the U.S. Food and Drug Administration
  • The company has accelerated the process of distributing its products beyond Canada by getting the Delta facility approved for exporting
  • Plant Veda is down 2.75 per cent, trading at $1.77 at 2:03 pm ET

Plant Veda (MILK) has received export approval from the Canadian Food Inspection Agency (CFIA).

The approval is for the company’s new facility in Delta, British Columbia.

The Vancouver plant-based-food company’s facility has also been registered with the U.S. Food and Drug Administration (FDA).

Due to strong demand, the company has accelerated the process of distributing its products beyond Canada by getting the Delta facility approved for exporting.

“We are very excited to have the new Delta facility approved for exporting to the United States. This is one step closer for Plant Veda to reach more consumers globally and help them in their shift to a healthier, plant-based lifestyle,” said Plant Veda CEO Sunny Gurnani.

Plant Veda has created plant-based dairy alternatives that are better than the original in terms of health and flavour.

Plant Veda is down 2.75 per cent, trading at $1.77 at 2:03 pm ET.

More From The Market Herald

" Komo Plant-Based Foods (CSE:YUM) is building out its U.S. expansion

Komo Plant-Based Foods (YUM) has appointed Caboodle Consulting LLC to support the company’s retail expansion in the United States.

" Your Answer to the Formula Shortage Crisis (TSX: BABY)

 (Image via Else Nutrition Holdings Inc.)
Perk Labs - CEO, Jonathan Hoyles.

" Perk Labs (CSE:PERK) enters Toronto market

Perk Labs (PERK) has signed a franchise agreement in downtown Toronto.

" Optimi (CSE:OPTI) cultivates first batch of mushrooms

Optimi Health (OPTI) successfully completed its first batch of psilocybin cubensis and functional mushrooms.